Understand the source comparison
How to Use Dihexa for Neurogenesis: Peptide Comparison
Dihexa HGF/c-Met pathway agonist. Promotes dendritic spine formation via AMPA receptor potentiation Yes. Lipophilic structure allows passive diffusion 1–5mg/day subcutaneous Once daily Most potent neurogenic peptide for synaptic density; requires precise recon
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Dihexa
- HGF/c-Met pathway agonist. Promotes dendritic spine formation via AMPA receptor potentiation
- Yes. Lipophilic structure allows passive diffusion
- 1–5mg/day subcutaneous
- Once daily
- Most potent neurogenic peptide for synaptic density; requires precise reconstitution; short half-life demands daily dosing
- Cerebrolysin
- Neurotrophic peptide mixture mimicking BDNF, NGF, CNTF activity
- Limited. Requires higher doses for CNS effect
- 5–30mL/day intramuscular or IV
- Daily or 5 days/week
- Clinically validated in stroke recovery; expensive per-dose cost; injection volume is limiting factor for some protocols
- P21
- CREB pathway activator. Derived from CNTF ciliary neurotrophic factor
- Yes. Intranasal delivery bypasses BBB
- 1–3mg/day intranasal
- Non-invasive administration; slower onset than injectable compounds; ideal for long-term cognitive maintenance research
- Semax
- Melanocortin receptor modulation + BDNF upregulation
- Yes. Intranasal route
- 300–600mcg/day intranasal
- 2–3 times daily
- Rapid anxiolytic effects; shorter action window requires multiple daily doses; less robust neurogenesis data than Dihexa
- NSI-189
- Hippocampal neurogenesis stimulant via unknown mechanism
- Yes. Oral bioavailability
- 40mg oral twice daily
- Twice daily
- Oral convenience; mechanisms poorly understood; Phase II trial data showed mixed results for depression endpoints